[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616821":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":18,"responsibleParty":32,"collaborators":18,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":18,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":18,"enrollmentInfo":43,"targetDuration":18,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":59,"whyStopped":18,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":18},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LINE Chatbot Intervention Group","EXPERIMENTAL","Participants receive usual care plus access to a visual interactive LINE chatbot designed to support self-management of treatment-related side effects during EGFR-TKI therapy.",[13],"Behavioral: Visual-Interactive LINE Chatbot",{"label":15,"type":16,"description":17,"interventionNames":18},"usual care","NO_INTERVENTION","Participants receive usual care, which consists of standard paper-based educational materials provided as part of routine clinical care, without access to the LINE chatbot.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BEHAVIORAL","Visual-Interactive LINE Chatbot","Participants receive access to a visual-interactive LINE chatbot designed to support self-management of EGFR-TKI-related side effects. The chatbot provides interactive and visualized educational content, symptom monitoring guidance, and self-care recommendations throughout the treatment period, in addition to usual care.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"LING-SIN HSU, MSN","CONTACT","+886-2-23123456","266942","a109700@ntuh.gov.tw",{"type":33,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100616821","effects-of-a-visual-interactive-line-chatbot-on-self-management-of-egfr-tki-related-side-effects-in-patients-with-lung-cancer-100616821",false,"NCT07310589","Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients With Lung Cancer","A Randomized Controlled Trial to Evaluate the Effects of a Visual-Interactive LINE Chatbot on Self-Management of EGFR-TKI-Related Side Effects in Patients With Lung Cancer","Inclusion Criteria:\n\n* Patients with newly diagnosed stage IIIB to IVB unresectable or inoperable non-small cell lung cancer (NSCLC), or those with first disease recurrence who are receiving oral targeted therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, with the ability to perform self-care activities.\n* Patients receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy, including gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib.\n* Willingness to participate in the study, with completion of the informed consent process and provision of written informed consent.\n* Ability to communicate in Chinese and to independently operate a smartphone and use the LINE application.\n\nExclusion Criteria:\n\n* Patients diagnosed with a second primary malignancy or multiple malignancies.\n* Patients receiving other anticancer treatments.","ALL","18 Years",{"count":44,"type":45},178,"ESTIMATED","INTERVENTIONAL",[48],"NA","This study aims to evaluate a visual interactive LINE chatbot designed to support self-management of treatment-related side effects among patients with advanced lung cancer receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy.\n\nPatients receiving EGFR-TKI treatment often experience long-term side effects that require ongoing self-management. In this randomized controlled trial, participants will be assigned to receive either usual care alone or usual care plus access to the LINE chatbot intervention, which provides visualized and interactive educational content for symptom monitoring and self-care.\n\nThe primary outcome of this study is self-management ability related to EGFR-TKI-associated side effects. Secondary outcomes include quality of life during treatment and overall satisfaction with the LINE chatbot intervention.",[51],"Non-Small Cell Lung Cancer",[53,54,55,56,57,58],"LINE Chatbot","EGFR-TKIs","side effects","Self-management ability","Quality of life","NSCLC","NOT_YET_RECRUITING","2026-08-10",{"date":62,"type":63},"2026-08-11","ACTUAL",{"date":65,"type":45},"2026-08-15",{"date":67,"type":45},"2028-06-30",{"name":5,"class":6}]